1. Home
  2. RPD vs OBX Comparison

RPD vs OBX Comparison

Compare RPD & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

N/A

Current Price

$14.44

Market Cap

746.5M

Sector

Technology

ML Signal

N/A

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$12.02

Market Cap

848.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPD
OBX
Founded
2000
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.5M
848.8M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
RPD
OBX
Price
$14.44
$12.02
Analyst Decision
Hold
Strong Buy
Analyst Count
24
5
Target Price
$15.50
★ $38.67
AVG Volume (30 Days)
★ 1.9M
541.6K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.16
N/A
Revenue
★ $685,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$95.75
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$9.60
52 Week High
$18.56
$39.00

Technical Indicators

Market Signals
Indicator
RPD
OBX
Relative Strength Index (RSI) 49.55 42.10
Support Level $11.04 $11.84
Resistance Level $18.56 $15.87
Average True Range (ATR) 1.25 1.60
MACD -0.14 -0.03
Stochastic Oscillator 25.25 43.34

Price Performance

Historical Comparison
RPD
OBX

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: